Jubilant Ingrevia Ltd Q3 FY2025 Concall Summary

Key Takeaways

• Portfolio transformation is delivering: EBITDA margin has climbed from 9.5% to 14% over the last 4–5 quarters, driven by a deliberate shift toward high-margin Specialty and Nutrition businesses and a structural cost takeout of over ₹100 cr.
• Pinnacle 345 sets an audacious destination: Management targets 3x revenue (₹12,000 cr) and 4x EBITDA (₹2,000 cr) in 5 years, with a bottom-up organic plan covering ₹10,000 cr and the remaining ₹2,000 cr to be bridged via M&A or new platforms.
• CDMO is the growth engine, with orders to prove it: A \$300 mn agro contract is under construction, a second is starting revenue mid-year, and the pharma pipeline has doubled in 6–9 months; management sees at least 5x CDMO growth in 2 years, with over 70% of that already backed by purchase orders.
• Cost leadership is a durable moat in a tough industry: While Chinese competitors run pyridine plants at 30–40% utilization, Jubilant operates at 70–80% and captured 70% of a US competitor’s volumes within six months of its closure.
• What to watch next quarter: The pace of CDMO revenue conversion as the second agro contract begins, any recovery in the depressed Acetyl business where destocking has bottomed out, and progress on the ₹100 cr annual cost-savings plan.

The Pinnacle 345 Vision

• The headline ambition: 3x revenue growth and 4x EBITDA growth over the next 5 years, taking the topline from ~₹4,200 cr to ₹12,000 cr and EBITDA to ₹2,000 cr, with a path to 17–20% ROCE.
• The organic bridge: A bottom-up plan delivers ~₹10,000 cr organically, leaving a ₹2,000 cr gap that management intends to fill through inorganic opportunities or entirely new platforms.
• The portfolio pivot: Specialty and Nutrition, currently ~40% and 15–18% of the portfolio respectively, are expected to become 75–80% of the business in 4–5 years, with Specialty alone taking a ~60% share. Exports will rise to 60–65% of revenue, with the US becoming a 20–25% market.
• The margin ambition: Management expects to exit at an EBITDA margin of at least 17–18%, driven by the mix shift toward higher-margin specialties and the permanent cost savings being embedded into operations.
• The capital discipline: A firm rule that nothing earning less than a 20% return will be invested in, with most growth capex funded through internal accruals as profitability rises and cash conversion touches 100%.

Deepak Jain: "We want to be the leader provider of innovative solutions in our core chemistry. I think the key words here, to focus on are 'innovation' and 'core chemistry'."

CDMO: The Growth Engine

• Agro CDMO is scaling fast: A \$300 mn contract with an innovator, announced in October, is under construction and will be ready by October/November this year, with revenues starting in Q4 FY26. A second contract with another innovator, involving modification of a multipurpose plant, will begin generating revenue by the middle of this calendar year.
• Pharma CDMO pipeline has doubled: Within the last 6–9 months, the funnel size has doubled and 12 molecules have been confirmed by customers. The business is shifting from pyridine/diketene derivatives to non-pyridine chemistry, with 50%+ of future CDMO revenue expected to be non-pyridine.
• Semiconductor CDMO is a new frontier: Within one year, a pipeline of 8–10 molecules has been built, with customers confirming kilogram volumes and samples already supplied to 3–4 customers. Management describes this as a multi-year journey where customers will take a few more years before outsourcing in a big way.
• The growth is contracted, not aspirational: Management states at least 5x CDMO growth in the next 2 years, with clarity already in hand for more than 70% of the purchase orders, meaning 3.5x is effectively secured. By FY30, the target is ~7x growth, supported by multiyear contracts with agro innovators for both existing and new molecules.
• Project mix is weighted toward early-stage innovation: 65% of molecules are in-phase (phase-1, phase-2, phase-3) and 35% are commercial, with the majority of the CDMO business conducted directly with innovators rather than generics players.
• Execution is being accelerated: Capex projects are being targeted for 12–14 month execution versus a typical 20–22 months, and business development efforts are being ramped up with new hires in the US, Europe, and Japan.

Ambrish Dixit: "We are looking at least 5x growth in the next 2 years. And I'm very pleased to share that we have already clarity for more than 70% of the POs in hand, so technically 3.5x anyways it will happen and then we are talking about taking it to another 2x."

Cost Leadership & Competitive Moat

• Pyridine utilization gap is structural: Despite global excess capacity where only 50% is utilized, Jubilant runs its plants at 70–80% consistently while Chinese competitors operate at 30–40%. The company is de-bottlenecking its pyridine plant this year to increase capacity, a signal of sustained demand for its output.
• Competitor exit became market-share gain: When a US competitor (Vertilabs) closed down, Jubilant captured 70% of their volumes within six to nine months, moving at speed to prevent Chinese competitors from taking the share.
• Chemical Intermediates is defending and expanding: Acetic anhydride market share in India has been maintained and increased to ~74% despite depressed demand. Market share in Europe has been held despite Ukraine war challenges, and share in the Rest of World market has grown significantly. Ethyl acetate has grown almost 30%, and acetaldehyde has increased almost 180% with exports beginning.
• The Acetyl cycle has bottomed: The anhydride business, driven by paracetamol and acetate (a big agrochemical molecule), has been through six to eight tough quarters with most customers running at 40–50% utilization. Destocking is now complete and conditions have bottomed out, though price recovery assumptions are modest given Chinese overcapacity.

Deepak Jain: "We are running our plants at 80% and that just shows that despite all the competition, price drop from the Chinese competitors, we are still competitive versus them and to an extent that they run their plants at 30-40% utilization and we are running at almost 70-80% consistently."

Structural Cost Takeout & Margin Levers

• ₹120 cr in savings already delivered: The savings came from renewable power and energy efficiency (boiler efficiency improved 9% via a centre of excellence), smarter power sourcing through exchange and short-term contracts plus a new long-term contract, a lean program delivering 20% productivity improvement across operations, supply chain, quality, maintenance, and projects, effluent treatment success at the Gajraula site, and 30 high-impact digital interventions including advanced process control in boiler trials.
• An additional ₹100 cr per year is targeted: Management has line of sight to systematic, permanent cost savings of ₹100 cr each year moving forward, with roughly 50% expected from energy in the next year, plus norm improvements and effluent treatment gains.
• Digital is a serious productivity lever: Over 200 digital interventions have been implemented, 26+ centres of excellence are operational, and 300 more interventions are in the pipeline. One facility has already won the World Economic Forum Lighthouse Network Award, the only chemical company globally in the 2024 cohort, with an aspiration to earn the designation for at least one more plant within 2 years.
• The savings are permanent, not cyclical: Management emphasizes that these are systematic savings that permanently take cost out of the business, not one-time gains that will reverse when volumes return.

Nutrition & Health Solutions: The Next Leg

• The ambition is to triple revenue by FY30: The Nutrition & Health Solutions segment aims to triple its topline and double its bottom line, taking EBITDA margin from ~12% to 18–20%.
• The mix is shifting decisively toward premium: Revenue from food, cosmetics, and specialty pre-mixes currently stands at 33% and will rise to 36% this year; by FY30, the target is 67%. This shift from commoditized animal nutrition toward human nutrition and cosmetics is the margin driver.
• Niacinamide is a leadership play: A cosmetics-grade and food-grade Vitamin B3 plant has been commissioned and is ramping up volumes, with management targeting the number one global position very soon.
• New products are entering human nutrition: Choline chloride and choline bitartrate for human nutrition and pharmaceuticals have been launched and are ramping up, with capex underway for a greenfield GMP plant to produce these at scale.
• New leadership has been installed: Vishal joined approximately 10 days before the call to lead the human nutrition business, bringing dedicated senior focus to the premiumization strategy.

Ashish Sinha: "Currently if you see, 33% of our revenue in nutrition and health solutions segment comes from food, cosmetics and speciality pre-mixes. This year, this will increase to 36%... By FY30, we will take it to 67%."

Organizational Transformation & R&D Catch-Up

• Leadership has been substantially refreshed: Approximately 50% of the leadership team has taken their roles in the last 1.5–2 years, a mix of internal promotions and external hires brought in to bridge capability gaps for specialty customer expectations. Key recent additions include a new CFO (Varun Gupta, 6 months), a new supply chain head (Birajeev, from a digital background), and a new nutrition business head (Vishal).
• R&D spend is doubling from a low base: Management acknowledges the company has historically under-invested in R&D, spending less than 1% of revenue compared to 2.5% at good Indian chemical companies. A new R&D centre in Greater Noida with ~150 Ingrevia engineers is now operational, and R&D spend as a percentage of revenue is expected to double in the coming years.
• Customer engagement has been rewired: Management has travelled extensively (Europe 4 times, US 2 times, Japan once, China once, SE Asia multiple times in the last year) and has shifted the conversation from pyridine to customers’ new molecules and CDMO acceleration. A key account management initiative mapped 30–35 big customers across 130+ products and met over 120 customers at the most senior level between March and September–October.
• The cultural shift is toward customer-centricity: The transformation from a pyridine-led commodity player to a specialty solutions company requires a fundamentally different approach to customers, and management frames this as the central organizational challenge.

Deepak Jain: "Even yesterday, some of our biggest customers were talking about pyridine but in the 2-hour session, we didn't talk about pyridine at all. Now, some of you won't even believe that Jubilant going to a customer and not even talking about Pyridine because Jubilant and pyridine are synonymous, but for 2 hours, all we talked about was what were their new molecules coming up, how can we accelerate some of those projects on the CDMO side."

Guidance & Commitments

Key Metrics